CareDx Promotes Living Donor Transplantation Through Employee Policy
The progressive CareDx Living Donor Employee Recovery Policy announced at ATC
BRISBANE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces a progressive Living Donor Employee Recovery Policy to support employees who donate an organ or bone marrow.
As part of the company’s commitment to the organ transplant community, CareDx will adopt a corporate policy to support employees who donate an organ or bone marrow to help save someone's life. The Living Donor Employee Recovery Policy was announced at the American Transplant Congress in Seattle, Washington alongside a presentation on the importance of living organ donation from Kevin Longino, CEO of the National Kidney Foundation.
“CareDx’s forward-thinking policy is an important step towards removing some of the barriers that living donors face such as paid time-off for donation and recovery and job security. Living organ donors are heroes and should be treated as such. We applaud CareDx for moving forward with an initiative that recognizes the importance of living organ donation and we strongly encourage other corporations to adopt similar policies,” said Longino, who is also a kidney transplant recipient.
“Since we started with this initiative, we have received endorsements or strong support from many organizations, including: The National Kidney Foundation, American Association of Kidney Patients, American Society of Transplantation, and American Society of Transplant Surgeons. Also we have seen many individuals showing their support. Besides being the right thing to do, the policy highlights our overall commitment to the field of transplantation,” says Peter Maag, CEO & President of CareDx.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum.
For more information, please visit: .
CONTACTS:
CareDx, Inc.
Sasha King
Chief Commercial Officer
Investor Relations
David Clair
Integrated Corporate Relations, Inc.
